Intranasal Administration of Nicotinamide Adenine Dinucleotide Alleviates Headaches Associated with Migraine Pain and Reduces Adverse Effects of Anxiety Disorders: A Case Report

WHITE1, A. PODESTA2, G. A. DYESS1, S. L. BROOM3, R. F. MESTAYER1,4.

1NAD Research, Inc., Springfield, LA; 2Podesta Wellness, Tulane Clin. Fac., New Orleans, LA; 3William Carey Univ., Hattiesburg, MS; 4Springfield Wellness Ctr., Springfield, LA

Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., Grant, R., Sachdev, P. (2019). Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: Rationale, biochemistry, pharmacokinetics, and outcomes. Antioxid Redox Signal, 30(2), 251-294. doi: 10.1089/ars.2017.7269

Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019). NAD + in brain aging and neurodegenerative disorders. Cell Metabolism30(4), 630–655. https://doi.org/10.1016/j.cmet.2019.09.001

Ross Grant, Jade Berg, Richard Mestayer, Nady Braidy, James Bennett, Susan Broom, & James Watson. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience11. https://doi.org/10.3389/fnagi.2019.00257

Gilmour BC, Gudmundsrud R, Frank J, Hov A, Lautrup S, Aman Y, Røsjø H, Brenner C, Ziegler M, Tysnes OB, Tzoulis C, Omland T, Søraas A, Holmøy T, Bergersen LH, Storm-Mathisen J, Nilsen H, Fang EF. Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and aging. Mech Ageing Dev. 2020 Mar;186:111208. doi: 10.1016/j.mad.2020.111208. Epub 2020 Jan 15. PMID: 31953124.

Figure 1. Technique of intranasal sphenopalatine ganglion block. Reproduced under Open Access charter from: Forrest A, Cantos A, Butani D. How We Do It: Sphenopalatine Ganglion Blockade for Migraine Treatment. Available from: https://dx.doi.org/10.25259/AJIR-34-2018 American Journal of Interventional Radiology (https://americanjir.com). 

Figure 1. License: This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License (https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.